/media/150986/新闻.jpg
WuXi STA Opens a New Large Scale Continuous Manufacturing Plant at Changzhou Site
Hero Banner
1
WuXi STA Opens a New Large Scale Continuous Manufacturing Plant at Changzhou Site
Headline

Company continues to enhance the flow chemistry platform for more sustainable production

Shanghai, China, July 15, 2022 - WuXi STA, a subsidiary of WuXi AppTec, today announced that it has opened a new continuous manufacturing (flow chemistry) plant at its Changzhou campus in China for large-scale active pharmaceutical ingredient (API) and advanced intermediate production. This new expansion marks the company's continuous effort to enhance its flow chemistry platform in response to the increasing customer demand for safe and sustainable pharmaceutical manufacturing. 

The new plant features 11 continuous production lines which support 20 types of challenging reactions, including low temperature metallo-organic reactions, photochemical reactions, high-temperature & high-pressure reactions, nitration reactions, ozonolysis, etc. With the opening of the new plant, WuXi STA now has multiple flow chemistry R&D labs and 25 continuous manufacturing lines in Shanghai Waigaoqiao, Shanghai Jinshan, and Changzhou sites in China.  

Committed to process safety and sustainability, WuXi STA started building its flow chemistry capability in 2014.  To date, WuXi STA has supported over 500 continuous manufacturing projects, including more than 20 late-stage and commercial projects. 

"We are witnessing a fast-growing customer demand driven by the extensive application of flow chemistry in the pharmaceutical industry," said Dr. Xiaoyong Fu, CTO and Head of API Business at WuXi STA. "As a trusted partner and a global enabler, we will continue to strengthen our flow chemistry platform and accelerate new therapeutics with safer and more cost-effective solutions to benefit patients in need while reducing the environmental impact of large-scale manufacturing."

Rich Text
2
About WuXi STA
Headline

WuXi STA, a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry with operations across Asia, North America and Europe. As a premier Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi STA offers our worldwide partners efficient, flexible, and high-quality solutions for integrated CMC (Chemical, Manufacturing, and Controls) solutions from preclinical to commercial uses. For more information, please visit http://www.STApharma.com.

Rich Text
中文
EN
  • Home 首页
  • {{menu.Name}} {{menu.Name}}
      • {{twoMenu.Name}} {{twoMenu.Name}}
        • {{threeMenu.Name}} {{threeMenu.Name}}
          • {{fourMenu.Name}}
    • {{twoMenu.Name}}
  • Home 首页
  • EN 中文

{{item.headBannerTitle}}

{{ item.title }}

{{ item.title }}

{{ item.title }}

  • About Us
  • News
  • Resource
  • Careers
  • Contact Us

Services & Solutions

  • API Process Development & Manufacturing
  • Drug Product Development & Manufacturing
  • Oligonucleotide CRDMO Service
  • Peptide CDRMO Service
  • Analytical Development & Quality Control
  • Global Regulatory Affairs CMC Support
  • 关于我们
  • 新闻和活动
  • 资源中心
  • 职业发展
  • 联系我们

服务和解决方案

  • 原料药工艺研发与生产
  • 制剂工艺研发与生产
  • 寡核苷酸
  • 多肽服务
  • 分析开发与质量控制
  • 全球申报事务药学支持

领英

药明康德

Copyright © 2020 STA Pharmaceutical Co. Ltd. Privacy Policy 隐私策略 Terms of Use 使用条款 沪公网安备 31011502018943号